Surprising Analyst 12-Month Target For VLUE
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 24 2024
0mins
Should l Buy BIO?
Source: NASDAQ.COM
ETF Analysis: The iShares MSCI USA Value Factor ETF (VLUE) has an implied analyst target price of $120.25, indicating a potential upside of 10.05% from its current trading price of $109.27.
Stock Performance Insights: Notable underlying holdings such as Expand Energy Corp, Bio-Rad Laboratories Inc, and Annaly Capital Management Inc show significant upside potential based on analysts' target prices, prompting questions about the validity of these targets amidst market developments.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BIO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BIO
Wall Street analysts forecast BIO stock price to rise
2 Analyst Rating
1 Buy
1 Hold
0 Sell
Moderate Buy
Current: 292.420
Low
340.00
Averages
357.50
High
375.00
Current: 292.420
Low
340.00
Averages
357.50
High
375.00
About BIO
Bio-Rad Laboratories, Inc. is engaged in developing, manufacturing, and marketing a range of products for the life science research and clinical diagnostics markets. The Company offers a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components. It operates through two segments: Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables used for biological research, biopharmaceutical production processes, food testing regimes, and science education. Its Clinical Diagnostics segment designs, manufactures, markets and supports test systems, informatics systems, test kits and specialized quality controls that serve clinical laboratories in the global diagnostics market. These products are sold to hospital laboratories, diagnostic reference laboratories, transfusion laboratories, and physician office laboratories.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
BIO RAD LABORATORIES STOCK FALLS 13.3% IN PREMARKET TRADING FOLLOWING Q4 RESULTS
- Market Reaction: Bio-Rad Laboratories shares experienced a decline of 13.3% in pre-market trading following the release of their Q4 results.
- Financial Performance: The Q4 results prompted investor concerns, leading to the significant drop in share value.
See More
Bio-Rad Laboratories Reports Q4 2025 Earnings Insights
- Revenue Growth: Bio-Rad reported net sales of approximately $693 million for Q4 2025, reflecting a 3.9% increase year-over-year; however, the gross margin fell short of expectations, indicating ongoing challenges in cost management.
- Product Line Performance: The Diagnostics segment returned to growth, driven by the annualization effect of the diabetes testing reimbursement change in China and large customer orders, while the Life Science division saw significant progress from the Stilla acquisition and strong QX700 digital PCR sales.
- Future Outlook: The company anticipates 2026 non-GAAP revenue growth between 0.5% and 1.5%, with a projected decline in Q1 year-over-year but expected sequential improvement in subsequent quarters, reflecting management's cautious optimism about market stabilization.
- Cash Flow and Buyback Plans: Free cash flow for 2026 is projected to be between $375 million and $395 million, with $285 million available for stock buybacks, demonstrating the company's strategic flexibility in capital management.
See More
U.S. Stocks Close Higher as Software Stocks Recover
- Market Recovery: The S&P 500 index rose by 0.05%, the Dow Jones Industrial Average by 0.10%, and the Nasdaq 100 by 0.18% on Friday, indicating a recovery after early losses, reflecting cautious optimism among investors regarding future economic prospects.
- Inflation Data Impact: The U.S. January Consumer Price Index rose by 2.4% year-over-year, below the expected 2.5%, marking the smallest increase in seven months, which may prompt the Fed to continue cutting rates, thus providing support for the stock market and alleviating concerns over rate hikes.
- Strong Software Stock Performance: Software stocks like Crowdstrike Holdings and ServiceNow rose over 4% and 3%, respectively, lifting the broader market and indicating a rebound in investor confidence in tech stocks, particularly amid rapid advancements in AI technology.
- Metal Stocks Retreat: Reports of the Trump administration's plans to narrow tariffs on steel and aluminum products led to declines in metal companies, with Century Aluminum falling over 7%, reflecting the negative impact of policy changes on the sector.
See More
US Stocks Edge Up, Led by Chipmakers' Gains
- Chipmaker Rebound: Applied Materials (AMAT) reported Q1 adjusted EPS of $2.38, surpassing the consensus of $2.21, leading to a 10% stock price increase that helped lift the broader market, indicating strong recovery potential in tech stocks.
- Inflation Data Impact: The US January CPI rose 2.4% year-over-year, below the expected 2.5%, which may prompt the Fed to continue cutting rates, with the 10-year T-note yield falling to 4.05%, providing support for the market.
- Earnings Performance: Over two-thirds of S&P 500 companies have reported earnings, with 76% exceeding expectations, and Q4 earnings growth is projected at 8.4%, demonstrating corporate resilience and restoring market confidence.
- Market Sentiment Fluctuations: Despite the overall market rise, concerns over AI persist, putting pressure on certain stocks, particularly in tech and logistics, reflecting investor caution regarding future economic prospects.
See More
US Stocks Decline Amid Rising AI Concerns
- Market Pressure Intensifies: The S&P 500 index fell by 0.22% and the Nasdaq 100 by 0.23%, reflecting investor concerns about AI technologies potentially disrupting multiple sectors, leading to a depressed market sentiment and extending Thursday's sharp losses.
- Inflation Data Impact: The US January Consumer Price Index rose by 2.4% year-over-year, below the expected 2.5%, marking the smallest increase in seven months, which drove the 10-year Treasury yield down to a 2.25-month low of 4.05%, potentially prompting the Fed to continue cutting rates.
- Earnings Optimism: Over two-thirds of S&P 500 companies have reported earnings, with 76% exceeding expectations, and Q4 earnings growth is projected at 8.4%, marking the tenth consecutive quarter of year-over-year growth, indicating resilience in corporate earnings.
- Tech Stocks Underperform: The so-called
See More
Pinterest Misses Q4 Revenue Expectations
- Revenue Shortfall: Pinterest reported Q4 revenue of $1.32 billion, falling short of analyst expectations of $1.33 billion, indicating competitive pressures that may undermine future investor confidence.
- Earnings Miss: The company posted adjusted earnings of 67 cents per share, below the anticipated 69 cents, reflecting challenges in profitability that could lead to shareholder scrutiny of management.
- Significant Stock Decline: Pinterest shares plummeted 19.5% to $14.95 in pre-market trading, a drastic move that may raise concerns about the company's future performance and influence investor decisions.
- Mixed Market Sentiment: U.S. stock futures showed mixed results, with Dow futures down about 0.2%, reflecting cautious market sentiment potentially linked to Pinterest's earnings report, further exacerbating investor unease.
See More
BIO RAD LABORATORIES STOCK FALLS 13.3% IN PREMARKET TRADING FOLLOWING Q4 RESULTS
- Market Reaction: Bio-Rad Laboratories shares experienced a decline of 13.3% in pre-market trading following the release of their Q4 results.
- Financial Performance: The Q4 results prompted investor concerns, leading to the significant drop in share value.
See More
Bio-Rad Laboratories Reports Q4 2025 Earnings Insights
- Revenue Growth: Bio-Rad reported net sales of approximately $693 million for Q4 2025, reflecting a 3.9% increase year-over-year; however, the gross margin fell short of expectations, indicating ongoing challenges in cost management.
- Product Line Performance: The Diagnostics segment returned to growth, driven by the annualization effect of the diabetes testing reimbursement change in China and large customer orders, while the Life Science division saw significant progress from the Stilla acquisition and strong QX700 digital PCR sales.
- Future Outlook: The company anticipates 2026 non-GAAP revenue growth between 0.5% and 1.5%, with a projected decline in Q1 year-over-year but expected sequential improvement in subsequent quarters, reflecting management's cautious optimism about market stabilization.
- Cash Flow and Buyback Plans: Free cash flow for 2026 is projected to be between $375 million and $395 million, with $285 million available for stock buybacks, demonstrating the company's strategic flexibility in capital management.
See More
U.S. Stocks Close Higher as Software Stocks Recover
- Market Recovery: The S&P 500 index rose by 0.05%, the Dow Jones Industrial Average by 0.10%, and the Nasdaq 100 by 0.18% on Friday, indicating a recovery after early losses, reflecting cautious optimism among investors regarding future economic prospects.
- Inflation Data Impact: The U.S. January Consumer Price Index rose by 2.4% year-over-year, below the expected 2.5%, marking the smallest increase in seven months, which may prompt the Fed to continue cutting rates, thus providing support for the stock market and alleviating concerns over rate hikes.
- Strong Software Stock Performance: Software stocks like Crowdstrike Holdings and ServiceNow rose over 4% and 3%, respectively, lifting the broader market and indicating a rebound in investor confidence in tech stocks, particularly amid rapid advancements in AI technology.
- Metal Stocks Retreat: Reports of the Trump administration's plans to narrow tariffs on steel and aluminum products led to declines in metal companies, with Century Aluminum falling over 7%, reflecting the negative impact of policy changes on the sector.
See More
US Stocks Edge Up, Led by Chipmakers' Gains
- Chipmaker Rebound: Applied Materials (AMAT) reported Q1 adjusted EPS of $2.38, surpassing the consensus of $2.21, leading to a 10% stock price increase that helped lift the broader market, indicating strong recovery potential in tech stocks.
- Inflation Data Impact: The US January CPI rose 2.4% year-over-year, below the expected 2.5%, which may prompt the Fed to continue cutting rates, with the 10-year T-note yield falling to 4.05%, providing support for the market.
- Earnings Performance: Over two-thirds of S&P 500 companies have reported earnings, with 76% exceeding expectations, and Q4 earnings growth is projected at 8.4%, demonstrating corporate resilience and restoring market confidence.
- Market Sentiment Fluctuations: Despite the overall market rise, concerns over AI persist, putting pressure on certain stocks, particularly in tech and logistics, reflecting investor caution regarding future economic prospects.
See More
US Stocks Decline Amid Rising AI Concerns
- Market Pressure Intensifies: The S&P 500 index fell by 0.22% and the Nasdaq 100 by 0.23%, reflecting investor concerns about AI technologies potentially disrupting multiple sectors, leading to a depressed market sentiment and extending Thursday's sharp losses.
- Inflation Data Impact: The US January Consumer Price Index rose by 2.4% year-over-year, below the expected 2.5%, marking the smallest increase in seven months, which drove the 10-year Treasury yield down to a 2.25-month low of 4.05%, potentially prompting the Fed to continue cutting rates.
- Earnings Optimism: Over two-thirds of S&P 500 companies have reported earnings, with 76% exceeding expectations, and Q4 earnings growth is projected at 8.4%, marking the tenth consecutive quarter of year-over-year growth, indicating resilience in corporate earnings.
- Tech Stocks Underperform: The so-called
See More
Pinterest Misses Q4 Revenue Expectations
- Revenue Shortfall: Pinterest reported Q4 revenue of $1.32 billion, falling short of analyst expectations of $1.33 billion, indicating competitive pressures that may undermine future investor confidence.
- Earnings Miss: The company posted adjusted earnings of 67 cents per share, below the anticipated 69 cents, reflecting challenges in profitability that could lead to shareholder scrutiny of management.
- Significant Stock Decline: Pinterest shares plummeted 19.5% to $14.95 in pre-market trading, a drastic move that may raise concerns about the company's future performance and influence investor decisions.
- Mixed Market Sentiment: U.S. stock futures showed mixed results, with Dow futures down about 0.2%, reflecting cautious market sentiment potentially linked to Pinterest's earnings report, further exacerbating investor unease.
See More
